New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on <i>EGFR</i>-Mutant Tumors
Stephanie P.L. Saw, Xiuning Le, Lizza Hendriks, Jordi Remón
Abstract
Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired resistance and evaluate the role of new drugs with novel mechanisms of action in the treatment landscape. In this chapter, we review treatment strategies of EGFR-mutant tumors in all stages, the mechanisms of acquired strategies, and novel therapies in this subset.
Topics & Concepts
DruggabilityMedicineLung cancerOncogeneAcquired resistanceOncologyMutantCancerCancer researchMutationInternal medicineBioinformaticsBiologyCell cycleGeneBiochemistryLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanisms